Pulmatrix (NASDAQ:PULM) Now Covered by StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Pulmatrix (NASDAQ:PULM) in a research note issued to investors on Tuesday. The firm set a “hold” rating on the biotechnology company’s stock.

Pulmatrix Price Performance

PULM stock opened at $6.04 on Tuesday. The firm has a market capitalization of $22.05 million, a P/E ratio of -2.29 and a beta of 0.99. Pulmatrix has a 52-week low of $1.55 and a 52-week high of $8.44. The company’s 50 day simple moving average is $2.73 and its 200-day simple moving average is $2.27.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.